3 FLUOROCHEMICAL SUBMISSION 2003 Click a Month back to year menu TOXICOLOGY, EPIDEMIOLOGY AND MEDICAL SURVEILLANCE October

%%' 0 O H (* ) 19:37 000112022608163 l D I C K A N S A I R & D IRD POl/O hk.Q.6- 06H-JL .Dainippon Ink & Chemicals, Inc 59200011-3 Takasago Takaishi-shi Facsimile Transmission 0sskilapa" NAME ............................Ms.

AR226-2214 Debbie J Mulrooney 11/15/2001 11:13 AM , To: Robert F Pinchot/DEV/AE/DuPont@DuPont cc: Steven L Grise/AE/DuPont@DuPont Subject: Consent Order Requirements - Particle Size Distribution Rob, Here is a spreadsheet with the particle size distribution, particle density and particulate scavenging coefficients based on the defaults in the ISC Users guide, i have left a blank slot for the vapor scavenging coefficients for when Steve and company finish calculating them.

AR226-2280 , Privileged and Confidential Attorney Work Product-Prepared in Anticipation o fLitigation Summary of Meeting with DAO `Representatives April 24. 2002 Attendees: DuPont Rob Pinchot Debbie Mulrooney Bob Ritchey Ann Bradley WVDEP-DAQ John Benedict Chris Arrington Dave Roberts WVDEP Dee Ann Staats Chris Negley (Office of Legal Services) Dave Watkins (Division of Water - Leader of GIST) Debbie Mulrooney provided an overview of the air modeling report that was sent to DAQ on April 19, 2002.

AR226-3192 DuPont-6541 TRADE SECRET Study Title H-24951: Biopersistence Screening 10-Dose Oral Gavage Study in Rats Laboratory Project ID: DuPont-6541 Author: Carol Finlay, B.A.

P-1 NORTHERN KENTUCKY OFFICE SUITE 340 1717 DIXIE HIGHWAY COVINGTON, KENTUCKY 41011-4704 606-331-2838 513-381-2838 ^ FAX: 513-381-6613 DAYTON, OHIO OFFICE SUITE 900 110 NORTH MAIN STREET DAYTON, OHIO 45402-1786 937-228-2838 FAX: 937-228-2816 Ro b e r t a .

P-1 COMPANY SANITIZED - Does not contain TSCA Confidential Business Information (CBI) DAUUN AZza _ 3730 fi o>2 <> DAIKIN AMERICA, INC. 905 State Docks Road (35601) P.O.

January 23, 2006 p ' f cP~7 E2- 0 E2 RECEIVED 0 P T CER OS JAN 2t AN i j , p j gm s.

MICHAEL i .

Jean B.

3M Specialty Materials June 28, 2000 c f yr - - 13M Center S65t.1P7a3u3l, M11N0055144-1000 0300 M 22.6- 062% r&(-5s>, m-o ---aonmmo ---F3aCo coom VIA EXPRESS MAIL Dr.

I -- Corporate Health Physics CorerOpa esc P50 Corporate Occupational Medicine Corres ra hepato 5 Pek 351333020 Corporate Product Responsibility i fssmbiiy lm Corporate Toxicology iene pers 3M Medical Department 3MCemer, 220-2E-02 POBox 33220 St.

T SB j(Oe_tt e_y--LhE nvicanscorners omnay "US Schnobrich/US-Corporate/3 M/US 03/08/2002 02:20 PM RepRcTED REDACTED To SuECorpS or EUSO Spat To Sara J.

3M MEDICAL DEPARTMANT CORPORATE TOXICOLOGY To: John Butenhoff Andrew Seacat From: Marvin Case Date: 5 April 2000 Subject: Liver Slide Review conclusons re 1 have completed the PFOS chronic mstyudmyi.crMosycofpiincdirnegvsiaerweofltishteed,lbivyergrsoeucpt,ioonns of the 14-week attached pages.

.